other material
confidence high
sentiment positive
materiality 0.65
EDIT-401 preclinical data shows ~90% mean reductions in LDL-C, Lp(a), ApoB in NHPs
Editas Medicine, Inc.
- Single dose achieved ≥90% mean reduction in LDL-C, rapid and dose-dependent, durable through 6 months in NHPs.
- Achieved ~90% mean reduction in Lp(a) and ApoB, supporting unified LDLR upregulation mechanism.
- Well-tolerated at therapeutically relevant dose 1.5 mg/kg; no adverse observations in ongoing GLP toxicology.
- Plans to submit CTN in Australia by mid-2026; first-in-human HeFH trial later in 2026; early human PoC data by end of 2026.
- Received positive pre-IND feedback from FDA on nonclinical package, CMC plans, and study design.